EC Number | Activating Compound | Comment | Organism | Structure |
---|---|---|---|---|
2.7.11.25 | progesterone | induces c-Mos expression | Xenopus sp. |
EC Number | Application | Comment | Organism |
---|---|---|---|
2.7.11.25 | medicine | gene amplification and corresponding increased Tpl-2 expression in some human breast cancers | Homo sapiens |
EC Number | Protein Variants | Comment | Organism |
---|---|---|---|
2.7.11.25 | additional information | MEKK1 knockdown in invasive human breast carcinoma cells leads to reduced uPA expression, cell migration, and invasiveness | Homo sapiens |
2.7.11.25 | additional information | MEKK1-4 knockout mice, MEKK3 knockout is embryo-lethal, displaying inadequate fetal-maternal vascularization. MEKK4 knockout is largely perinatal lethal, and associated with defective neural tube closure, shows loss of JNK and p38 activation. MEKK1-2 knockouts are associated with impaired tissue remodeling associated with wound healing and homeostasis, expression of JunB and Fra-2 is markedly increased in MEKK1-deficient mouse fibroblasts. MLK3-deficient mice are viable and fertile with only a mild defect in the epidermal tissue of the dorsal midline. Mouse embryos deficient in either B-Raf or C-Raf die before day E12.5. A-Raf deficient mice die perinatally at 1-3 weeks of age. Tpl2-deficient mice are viable and appear indistinguishable from littermates, produce reduced levels of TNFalpha in response to LPS injection, are resistant to LPS/D-galactosamine-induced pathology. TAK1-deficient mouse embryo fibroblasts show decreased IL-1beta-induced IL-6 expression, TAK1-deficient keratinocytes develop a severe postnatal inflammation, loss of MEKK1 does not alter the course of tumorigenesis or inhibit primary tumor growth, intimal hyperplasia is significantly reduced | Mus musculus |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
2.7.11.25 | BAY 43-9006 | c-Raf inhibitor, shows promising response rate in patients with primary renal cell carcinomas | Homo sapiens | |
2.7.11.25 | CEP-1347 | inhibits MLKs and is well tolerated in human trials, does not perform in trials for neurodegenerative disorders such as Parkinson´s disease | Homo sapiens |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
2.7.11.25 | Homo sapiens | - |
- |
- |
2.7.11.25 | Mus musculus | - |
- |
- |
2.7.11.25 | Rattus norvegicus | - |
- |
- |
2.7.11.25 | Xenopus sp. | - |
- |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
2.7.11.25 | breast carcinoma cell | - |
Homo sapiens | - |
2.7.11.25 | carcinoma cell line | A-Raf is rarely mutated in human cancers | Homo sapiens | - |
2.7.11.25 | embryo | - |
Mus musculus | - |
2.7.11.25 | fibroblast | constitutive c-Mos expression transforms fibroblasts | Mus musculus | - |
2.7.11.25 | keratinocyte | - |
Mus musculus | - |
2.7.11.25 | MOLT-4 cell | mutated A-Raf | Homo sapiens | - |
2.7.11.25 | oocyte | - |
Xenopus sp. | - |
2.7.11.25 | renal cell carcinoma cell | c-Raf | Homo sapiens | - |
2.7.11.25 | thymoma cell | Tpl-2 isolated from Moloney leukemia virus-induced thymoma cells | Rattus norvegicus | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.7.11.25 | ATP + ERK5 | - |
Mus musculus | ADP + phosphorylated ERK5 | - |
? | |
2.7.11.25 | additional information | MEKK3 is required for IL-1R and LPS-induced IL-6 production in fibroblasts | Mus musculus | ? | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
2.7.11.25 | A-Raf | - |
Mus musculus |
2.7.11.25 | B-Raf | - |
Mus musculus |
2.7.11.25 | c-mos | - |
Mus musculus |
2.7.11.25 | c-mos | - |
Xenopus sp. |
2.7.11.25 | C-Raf | - |
Mus musculus |
2.7.11.25 | C-Raf | - |
Homo sapiens |
2.7.11.25 | MEKK1 | - |
Mus musculus |
2.7.11.25 | MEKK1 | - |
Homo sapiens |
2.7.11.25 | MEKK2 | - |
Mus musculus |
2.7.11.25 | MEKK2 | - |
Homo sapiens |
2.7.11.25 | MEKK3 | - |
Mus musculus |
2.7.11.25 | MEKK3 | - |
Homo sapiens |
2.7.11.25 | MEKK4 | - |
Mus musculus |
2.7.11.25 | MEKK4 | - |
Homo sapiens |
2.7.11.25 | mitogen-activated protein kinase kinase kinase | - |
Mus musculus |
2.7.11.25 | mitogen-activated protein kinase kinase kinase | - |
Homo sapiens |
2.7.11.25 | mitogen-activated protein kinase kinase kinase | - |
Rattus norvegicus |
2.7.11.25 | mitogen-activated protein kinase kinase kinase | - |
Xenopus sp. |
2.7.11.25 | MKKK | - |
Mus musculus |
2.7.11.25 | MKKK | - |
Homo sapiens |
2.7.11.25 | MKKK | - |
Rattus norvegicus |
2.7.11.25 | MKKK | - |
Xenopus sp. |
2.7.11.25 | MKL3 | - |
Mus musculus |
2.7.11.25 | MLK | - |
Homo sapiens |
2.7.11.25 | TAK1 | - |
Mus musculus |
2.7.11.25 | TPL-2 | - |
Mus musculus |
2.7.11.25 | TPL-2 | - |
Homo sapiens |
2.7.11.25 | TPL-2 | - |
Rattus norvegicus |